Previous 10 | Next 10 |
HAYWARD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace...
2024-02-23 16:18:31 ET More on Benitec Seeking Alpha’s Quant Rating on Benitec Historical earnings data for Benitec Financial information for Benitec Read the full article on Seeking Alpha For further details see: Benitec Biopharma files fo...
2024-02-13 09:11:23 ET More on Benitec Seeking Alpha’s Quant Rating on Benitec Historical earnings data for Benitec Financial information for Benitec Read the full article on Seeking Alpha For further details see: Benitec GAAP EPS of -$2.64
-First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023- -Data Safety Monitoring Board Review for First Subject Completed After Day 28 Study Visit- -Second Subject Scheduled to Receive BB-301 in February 2024- -23 Subjects ...
Verde Clean Fuels Inc. (VGAS) is expected to report for Q4 2023 Pioneer Bancorp Inc. (PBFS) is expected to report for Q2 2024 Equity Commonwealth of Beneficial Interest (EQC) is expected to report $0.27 for Q4 2023 monday.com Ltd. (MNDY) is expected to report $-0.31 for Q4 2023 As...
HAYWARD, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace&...
HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (&...
HAYWARD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (&...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-06-30 Humanigen Inc. (HGEN) is expected to report for Q2 2023 Ever-Glory International Group Inc. (EVKG) is expected to report for quarter end 2023-06-30 SunCar Technology Group Inc. (SDA) is expected to ...
News, Short Squeeze, Breakout and More Instantly...
Benitec Biopharma Limited Company Name:
BNTC Stock Symbol:
NASDAQ Market:
Benitec Biopharma Limited Website:
2024-07-16 20:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-The post-dose average values for Total Pharyngeal Residue (i.e., the amount of solid food or liquid material remaining in the pharynx after the first swallow) remained meaningfully reduced at the 180-day post-dose assessment following the administration of the low dose of gene therapy BB-301 as ...
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace ...